Skip to main content
. 2020 Oct 27;10(4):1751–1761. doi: 10.3233/JPD-202058

Table 3.

Summary of treatment-emergent adverse events

Patients with Treatment-Emergent Adverse Events (TEAEs), n (%) Safety Population (N = 47)
Any TEAE 21 (44.7)
Any serious TEAE 1 (2.1)
TEAEs by MedDRA preferred term
  Fall 4 (8.5)
  Nausea 3 (6.4)
  Diarrhea 2 (4.3)
  Edema 2 (4.3)
  Skin abrasion 2 (4.3)
  Urinary tract infection 2 (4.3)
  Abdominal pain 1 (2.1)
  Abnormal dreams 1 (2.1)
  Blood glucose increased 1 (2.1)
  Blood pressure increased 1 (2.1)
  Colitis 1 (2.1)
  Constipation 1 (2.1)
  Contusion 1 (2.1)
  Dizziness 1 (2.1)
  Gastritis 1 (2.1)
  Gout 1 (2.1)
  Hallucination, auditory 1 (2.1)
  Hallucination, visual 1 (2.1)
  Hypertonia 1 (2.1)
  Hypothyroidism 1 (2.1)
  Illusion 1 (2.1)
  Insomnia 1 (2.1)
  Laceration 1 (2.1)
  Mental impairment 1 (2.1)
  Muscle strain 1 (2.1)
  Non-cardiac chest pain 1 (2.1)
  Palpitations 1 (2.1)
  Peripheral swelling 1 (2.1)
  Presyncope 1 (2.1)
  Rapid eye movement sleep behavior 1 (2.1)
 disorder
  Suicidal ideation 1 (2.1)
  Supraventricular extrasystoles 1 (2.1)
  Vomiting 1 (2.1)

MedDRA, Medical Dictionary for Regulatory Activities, Version 20.0.